Skip to main content
Clinical Trials/NCT03558984
NCT03558984
Terminated
Phase 3

Prospective, Multicenter, Randomized, Parallel Controlled, Two Arms, Single Blind, Study to Assess the Efficacy and Safety of D-PLEX Administered Concomitantly With the SOC IV Prophylactic Antibiotic Treatment vs. SOC in Prevention of Post-Cardiac Surgery Sternal Infections

PolyPid Ltd.3 sites in 2 countries2 target enrollmentDecember 17, 2019

Overview

Phase
Phase 3
Intervention
D-PLEX
Conditions
Surgical Site Infection
Sponsor
PolyPid Ltd.
Enrollment
2
Locations
3
Primary Endpoint
Sternal Wound Infection rate
Status
Terminated
Last Updated
3 years ago

Overview

Brief Summary

Prospective, Multinational, Multicenter, Randomized, Parallel Controlled, Two arms, Single Blind, Study to Assess the Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SOC) IV Prophylactic Antibiotic Treatment vs. SOC in Prevention of Post-Cardiac Surgery Sternal Infections.

Study to assess D-PLEX efficacy and safety in preventing sternal infections over a period of 90 days (3 months) post cardiac surgery with median sternotomy, in patients with high risk for infection compared to the control arm.

Detailed Description

This is Phase III study to evaluate the anti-infective efficacy and safety of D-PLEX, a new formulation of extended release of Doxycycline, over a period of 3 months post operation by preventing sternal infection post cardiac surgery in patients above the age of 18, including high risk patients for infection. Study will be conducted in about 45 sites in US (about 15 sites), Europe and Israel, recruitment period will last about 18 months. D-PLEX will be administered as a single application. For subjects randomized to the investigational treatment arm, D-PLEX treatment will be applied at the end of the index surgery just before closing the chest, as an adjunct to the SOC prophylactic antibiotic treatment. For subjects randomized to the control arm, the surgical treatment will be as per the SOC. Pre- and post-operative care for both arms will be performed per site SOC. Patients will followed-up during 6 months after surgery.

Registry
clinicaltrials.gov
Start Date
December 17, 2019
End Date
October 24, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects scheduled to elective and/or urgent median sternotomy for cardiac surgery, who are preoperative hemodynamically stable.
  • Males and females.
  • Subjects age of 18 and older.
  • Subjects with both Diabetes Mellitus AND BMI≥30 OR
  • Diabetes Mellitus/BMI≥30 AND at least one of the following:
  • Current/Previous smoking history ≥30 pack year
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Female of childbearing potential should have a negative serum pregnancy test prior to index procedure.
  • Note: All female of childbearing potential must agree to use a highly effective method of contraception (such as double barrier, oral or parenteral hormonal, intrauterine device and spermicide) consistently and correctly for the duration of the study.
  • Subject is willing and able to provide a signed Informed Consent Form and is willing and able to comply with study's procedures including follow-up visits.

Exclusion Criteria

  • Subjects undergoing partial sternotomy.
  • Subjects with any preoperative active significant infection.
  • Subjects that received oral or IV doxycycline during the last 4 weeks prior to screening.
  • Subjects with sensitivity to doxycycline and/or to tetracycline family of drugs and/or other study drug ingredients.
  • Subjects with known allergies to more than 3 substances. (An allergy questionnaire will be filled during the screening process).
  • Subjects with history of allergic/hypersensitivity reaction to any substance having required hospitalization and/or treatment with intra-venous steroids/epinephrine or in the opinion of the investigator the patient is at high risk of developing severe allergic/hypersensitivity reactions.
  • Subjects with uncontrolled Asthma (GINA III-IV).
  • Subjects with chronic urticaria.
  • Immunocompromised subjects from any reason, at screening.
  • Subjects with renal failure requiring dialysis.

Arms & Interventions

D-PLEX + SOC

For subjects randomized to the investigational treatment arm, D-PLEX treatment will be applied at the end of the index surgery just before closing the chest, as an adjunct to the SOC prophylactic antibiotic treatment.

Intervention: D-PLEX

D-PLEX + SOC

For subjects randomized to the investigational treatment arm, D-PLEX treatment will be applied at the end of the index surgery just before closing the chest, as an adjunct to the SOC prophylactic antibiotic treatment.

Intervention: Standard of Care

Standard of Care

For subjects randomized to the control arm, the surgical treatment will be as per the SOC.

Intervention: Standard of Care

Outcomes

Primary Outcomes

Sternal Wound Infection rate

Time Frame: within 90 days (3 months) post sternotomy for cardiac surgery

Infection rate as measured by the proportion of subjects with a sternal wound infection event. Sternal wound infection is composed of Deep Sternal Wound Infection (DSWI) \& Superficial Sternal Wound Infection (SSWI). Mortality from any reason within 90 days (3 months) post sternotomy, will be analyzed as treatment failure.

Secondary Outcomes

  • Number of surgical re-interventions(90 days (3 months) post sternotomy)
  • Hospitalization days(90 days)
  • Average ASEPSIS assessment score(90 days (3 months) post sternotomy)
  • Superficial Sternal Wound Infections (SSWI)(90 days (3 months) post sternotomy)
  • Deep Sternal Wound Infections (DSWI)(90 days (3 months) post sternotomy)
  • Determination of susceptibility to Doxycycline(90 days (3 months) post sternotomy)
  • Mortality rate associated with Sternal Wound Infection (SWI)(90 days (3 months) post sternotomy)

Study Sites (3)

Loading locations...

Similar Trials

Unknown
Phase 3
Naloxone HCl PR Tablets in Patients With Opioid Induced ConstipationOpioid-Induced Constipation
NCT03687268Develco Pharma Schweiz AG1,500
Completed
Phase 3
DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection FractionHeart Failure With Reduced Ejection Fraction (HFrEF)
NCT03877237AstraZeneca313
Completed
Phase 3
DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection FractionHeart Failure With Preserved Ejection Fraction (HFpEF)
NCT03877224AstraZeneca504
Active, not recruiting
Not Applicable
Multicentre, prospective, comparative, randomized, double-blind, double-dummy study to assess the efficacy and safety of cefditoren pivoxil versus ciprofloxacin in acute uncomplicated cystitis.Estudio multicéntrico, prospectivo, comparativo, aleatorizado, doble ciego y doble enmascarado para evaluar la eficacia y seguridad de cefditoren pivoxilo vs. ciprofloxacino en cistitis aguda no complicada.Cistitis aguda no complicada en mujeres no embarazadas: patología caracterizada por disuria, dolor suprapúbico, polaquiuria y/o tenesmo en combinación con bacteriuria y piuria. Sin patología renal asociada, disfunción urológica u obstrucción.Acute uncomplicated cystitis in non-pregnant women: pathology characterized by dysuria, suprapubic pain, frequency and/or urgency in combination with bacteriuria and pyuria. No renal pathology, urological dysfunction or obstruction is present.MedDRA version: 9.1Level: LLTClassification code 10000699Term: Acute cystitis (excl in pregnancy)
EUCTR2007-001486-15-ESTEDEC-MEIJI FARMA, S.A.580
Active, not recruiting
Not Applicable
Multicentre, prospective, comparative, randomized, double-blind, double-dummy study to assess the efficacy and safety of cefditoren pivoxil versus ciprofloxacin in acute uncomplicated cystitis.Acute uncomplicated cystitis in non-pregnant women, defined as: a clinical syndrome characterized by dysuria, suprapubic pain, frequency and/or urgency in combination with bacteriuria and pyuria. No renal pathology, urological dysfunction or obstruction is present.MedDRA version: 9.1Level: LLTClassification code 10000699Term: Acute cystitis (excl in pregnancy)
EUCTR2007-001486-15-GRTEDEC-MEIJI FARMA, S.A.580